Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...
Morningstar16d
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...
Medscape4d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
The Victoria Advocate17d
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...
Fast Company28d
GLP-1 drugs like Ozempic may have health benefits, but they come with risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.
ahajournals.org23d
Abstract 52: Glucagon-like peptide-1 receptor agonists use and outcomes in Cardiac Amyloidosis patients: A Propensity Matched Analysis
Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...
GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...
Medscape14h
New GLP-1 Data Reinforce CV Benefit
Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...
Frontiers19d
Proglucagon-Derived Peptides Expression and Secretion in Rat Insulinoma INS-1 Cells
Since proglucagon encodes multiple peptides including glucagon, glucagon-like-peptide-1 (GLP-1), GLP-2, oxyntomodulin, and glicentin, their specific expression and secretion are technically ...
People are microdosing Ozempic, aka GLP-1, in the name of wellness. We asked experts to weigh in on the benefits
Taking tiny doses of GLP-1 medication has been touted for weight management, perimenopause symptoms, even longevity. But is ...
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...